Kidney-sparing treatment for upper tract urothelial cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how well patients do when they have kidney-sparing treatment (instead of complete kidney removal) for upper tract urothelial carcinoma. It helps doctors understand which patients can safely avoid losing their kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with upper tract urothelial carcinoma (cancer of the kidney or ureter lining).
- You have chosen not to have full kidney removal surgery, or your doctor says a kidney-sparing approach is right for you.
- You are willing to come back for regular follow-up visits.
- You must sign a consent form agreeing to take part in the study.
- You cannot have had any prior treatments for this cancer, like chemotherapy, radiation, or immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments to save the kidney in people with high-risk upper tract urothelial carcinoma. The goal is to remove the cancer while keeping the kidney working, which may be an option if your cancer is at an early stage and your kidney function is good enough.
This trial tests a combination of an oral targeted drug (DV) and an immunotherapy (Toripalimab) to preserve kidney function in people with high-risk upper tract urothelial cancer (UTUC) who cannot have their kidney and ureter removed. It is for patients with only one kidney, reduced kidney function, or cancer in both ureters.
This study checks tumor DNA found in blood and urine to see who is at higher risk of the cancer coming back after surgery. It may help doctors identify “minimal residual disease,” meaning tiny amounts of cancer that can remain after treatment.
This trial tests whether giving chemotherapy before surgery can help people with high-risk upper tract urothelial cancer (a cancer in the kidney or ureter). The goal is to see if it improves outcomes for those who are healthy enough to receive cisplatin-based chemotherapy and undergo surgery.
This trial is for people diagnosed with a rare type of cancer in the upper urinary tract (UTUC). Researchers hope to learn more about this condition and find better ways to treat it.
This study watches people with upper tract urothelial cancer who are having surgery to remove the kidney and ureter. It aims to collect information to better understand the disease and improve future care.
Hear when a new Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.